Ortho Dermatologics

Alternate name: Ortho Dermatologics, Inc.

Country: US

Crossref ID: 100019507

DOI: 10.13039/100019507

OpenAlex ID: F4320318898

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

2019 · Craig A. Elmets, Craig L. Leonardi, et al. · Journal of the American Academy of Dermatology · 503

Guidelines of care for the management of acne vulgaris

2024 · Rachel V. Reynolds, Howa Yeung, et al. · Journal of the American Academy of Dermatology · 497

PDF

Guidelines of care for the management of atopic dermatitis in adults with topical therapies

2023 · Robert Sidbury, Ali Alikhan, et al. · Journal of the American Academy of Dermatology · 212

PDF

Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults

2019 · J.I. Silverberg, J.M. Gelfand, et al. · British Journal of Dermatology · 199

PDF

Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults

2018 · Jonathan I. Silverberg, Joel M. Gelfand, et al. · Annals of Allergy Asthma & Immunology · 169

PDF

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

2021 · Andrew Blauvelt, Jonathan I. Silverberg, et al. · Journal of the American Academy of Dermatology · 160

PDF

Should biologics for psoriasis be interrupted in the era of COVID-19?

2020 · Mark Lebwohl, Ryan Rivera-Oyola, et al. · Journal of the American Academy of Dermatology · 153

PDF

Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis

2020 · Amy S. Paller, Linda Stein Gold, et al. · Journal of the American Academy of Dermatology · 138

PDF

Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( IXORA ‐ PEDS )

2020 · A.S. Paller, M.M.B. Seyger, et al. · British Journal of Dermatology · 111

PDF

Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database

2018 · R.B. Warren, K. Reich, et al. · British Journal of Dermatology · 106

PDF

Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials

2024 · Jonathan I. Silverberg, Lawrence F. Eichenfield, et al. · Journal of the American Academy of Dermatology · 104

PDF

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

2022 · Alice B. Gottlieb, Atul Deodhar, et al. · Acta Dermato Venereologica · 99

PDF

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments

2021 · Joel M. Gelfand, April W. Armstrong, et al. · Journal of the American Academy of Dermatology · 97

PDF

Clinical Goals and Barriers to Effective Psoriasis Care

2018 · Bruce E. Strober, Joelle M. van der Walt, et al. · Dermatology and Therapy · 97

PDF

Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study

2024 · James D. Chalmers, Michal Shteinberg, et al. · European Respiratory Journal · 87

Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice

2021 · Valerie D. Callender, Hilary Baldwin, et al. · American Journal of Clinical Dermatology · 87

PDF

Oral Griseofulvin Remains the Treatment of Choice for Tinea Capitis in Children

2000 · Michelle L. Bennett, Alan B. Fleischer, et al. · Pediatric Dermatology · 86

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial

2019 · Luis Puig, Mark Lebwohl, et al. · Journal of the American Academy of Dermatology · 80

PDF

Comparison of Men and Women With Axial Spondyloarthritis in the US-based Corrona Psoriatic Arthritis/Spondyloarthritis Registry

2021 · Philip J. Mease, Robert R. McLean, et al. · The Journal of Rheumatology · 72

PDF

Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study

2020 · Abby S. Van Voorhees, Linda Stein Gold, et al. · Journal of the American Academy of Dermatology · 72

Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists

2021 · Bruce Strober, Nirali Kotowsky, et al. · Dermatology and Therapy · 71

PDF

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

2019 · April Armstrong, Carle Paul, et al. · Dermatology and Therapy · 65

PDF

Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)

2020 · Mark Lebwohl, Leon Kircik, et al. · Journal of the American Academy of Dermatology · 64

PDF

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis

2022 · April Armstrong, Kyle Fahrbach, et al. · Dermatology and Therapy · 63

PDF

Atopic Dermatitis in US Adults: From Population to Health Care Utilization

2019 · Jonathan I. Silverberg, Joel M. Gelfand, et al. · The Journal of Allergy and Clinical Immunology In Practice · 63

Works count: 312

Citation count: 6,772

H-index: 45

I10-index: 127

2-year mean citedness: 11.9

Awards count: 0